EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

CXCL13: a common target for immune-mediated inflammatory diseases

Lu Hui, Ye Li, Meng-Ke Huang, Yong-Mei Jiang, Ting Liu

Clinical and Experimental Medicine · 24.10.2024 · 24 (1)

DOI: 10.1007/s10238-024-01508-8 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Experimental Medicine, online erschienen am 24.10.2024. Verfasst von Lu Hui und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, West China Second University Hospital, and Key Laboratory of Obstetric and Gynecologic and Pediatric Diseases and …. Hauptthemen laut MEDLINE: Chemokine CXCL13, Inflammation. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 138 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sichuan Provincial Science and Technology Support Program, Sichuan Medical Association Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CXCL13 is a chemokine that plays an important role in the regulation and development of secondary lymphoid organs. CXCL13 is also involved in the regulation of pathological processes, particularly inflammatory responses, of many diseases. The function of CXCL13 varies depending on the condition of the host. In a healthy condition, CXCL13 is mainly secreted by mouse stromal cells or human follicular helper T cells, whereas in diseases conditions, they are produced by human peripheral helper T cells and macrophages in non-lymphoid tissues; this is termed ectopic expression of CXCL13. Ectopic CXCL13 expression is involved in the pathogenesis of various immune-mediated inflammatory diseases as it regulates the migration of B lymphocytes, T lymphocytes, and other immune cells in inflammatory sites as well as influences the expression of inflammatory factors. Additionally, ectopic expression of CXCL13 plays a key role in ectopic lymphoid organ formation. In this review, we focused on the sources of CXCL13 in different conditions and its regulatory mechanisms in immune-mediated inflammatory diseases, providing novel ideas for further research on targeting CXCL13 for the treatment of immune-mediated inflammatory diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chemokine CXCL13InflammationHumansAnimalsMiceMacrophagesB-Lymphocytes

Stichwörter der Autor:innen

CXCL13ELOsIMIDsImmune-mediated inflammatory diseasesInflammatory response

Substanzen

Chemokine CXCL13CXCL13 protein, human

Autor:innen und Institutionen

  • Department of Laboratory Medicine, West China Second University Hospital, and Key Laboratory of Obstetric and Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education, Sichuan University, No. 20, Se…
  • State Key Laboratory of Biotherapy and Cancer Center/National Collaborative Innovation Center for Biotherapy, Sichuan University, Chengdu, People's Republic of China. liuting88823@163.com.

Förderung

  • Sichuan Provincial Science and Technology Support Program
  • Sichuan Medical Association Project

Zitieren

APA

Hui, L., Li, Y., Huang, M. K., Jiang, Y. M., & Liu, T. (2024). CXCL13: a common target for immune-mediated inflammatory diseases. Clinical and Experimental Medicine, 24(1). https://doi.org/10.1007/s10238-024-01508-8

Vancouver

Hui L, Li Y, Huang MK, Jiang YM, Liu T. CXCL13: a common target for immune-mediated inflammatory diseases. Clinical and Experimental Medicine. 2024;24(1). doi:10.1007/s10238-024-01508-8

BibTeX
@article{Hui2024,
  author = {Hui, Lu and Li, Ye and Huang, Meng-Ke and Jiang, Yong-Mei and Liu, Ting},
  title = {CXCL13: a common target for immune-mediated inflammatory diseases},
  journal = {Clinical and Experimental Medicine},
  year = {2024},
  volume = {24},
  number = {1},
  doi = {10.1007/s10238-024-01508-8}
}
Kostenlos starten →